Physician profile
Sunja Tate
NPI 1124411004
$798.46
in general payments reported to CMS, 2019-2025
12 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $130 · 2022: $86.78 · 2023: $132 · 2024: $232 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $581.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $169.14 | 2024 | |
| Merck Sharp & Dohme LLC | $139.43 | 2022-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Corium, LLC | $110.97 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $88.05 | 2021-2023 | Bexsero, Pediarix, Menveo |
| Sanofi Pasteur INC. | $55.71 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.82 | 2021 | |
| Pfizer INC. | $51.92 | 2025 | |
| Supernus Pharmaceuticals, INC. | $47.34 | 2021 | |
| Collegium Pharmaceutical, INC. | $30.11 | 2025 | Jornay Pm |
| Roche Diagnostics Corporation | $19.52 | 2025 | Navify Poc Operations |
| Astrazeneca Pharmaceuticals Lp | $18.21 | 2024 | Flumist Quadrivalent |
| Quidel Corporation | $13.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunja Tate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.